Chromodomain-helicase-DNA-binding protein 5 (CHD5)

Chromodomain-helicase-DNA-binding protein 5 (CHD5) is an ATP-dependent chromatin remodeling factor and transcriptional regulator, predominantly expressed in neurons and testis, and essential for chromatin organization, cell cycle control, and gene transcription[2][5][6]. Structurally, CHD5 is part of the SNF2 superfamily, containing paired plant homeodomains (PHDs), chromodomains, and a central ATPase/helicase domain[3][4][5]. It is a component of the nucleosome remodeling and deacetylase complex (NuRD), facilitating chromatin-based transcriptional repression and activation. CHD5 acts as a tumor suppressor gene by regulating expression of key cell cycle inhibitors such as p16 and p19Arf, maintaining genome integrity, and suppressing cellular proliferation[1][2][3][5][6]. Inactivating mutations and promoter methylation of CHD5 are common in various cancers, especially neuroblastoma, leading to loss of tumor suppressor function and poor prognosis[2][4]. Mouse and human data also implicate CHD5 in the chromatin packaging process necessary for sperm maturation, with deficiency causing infertility[3]. As a disease biomarker, low CHD5 expression or hypermethylation facilitates disease monitoring and prognosis assessment[2][4][5]. There are no direct drugs targeting CHD5, but the pathway's epigenetic regulation provides potential for therapeutic intervention via reversal of gene silencing[2][3].

Other names

CHD-5KIAA0444ATP-dependent helicase CHD5PMNDSChromodomain helicase DNA binding protein 5

Drugs would theoretically act by modulating chromatin remodeling, epigenetic silencing/activation, or restoring expression of tumor suppressor pathways if targeting CHD5[2][3]. In cancers, pathogenesis often involves promoter methylation-mediated silencing, so epigenetic drugs (e.g., DNMT inhibitors, HDAC inhibitors) could be relevant adjuncts[2].